	US 12,473,338 B2
	Targeted engineered interferon and uses thereof
Nikolai Kley, Waltham, MA (US); Lennart Zabeau, Ghent (BE); and Jan Tavernier, Ghent (BE)
Assigned to Orionis Biosciences, Inc., Waltham, MA (US); and Orionis Biosciences BV, Ghent (BE)
Filed by Orionis Biosciences, Inc., Waltham, MA (US); and Orionis Biosciences BV, Ghent (BE)
Filed on Dec. 24, 2020, as Appl. No. 17/133,782.
Application 17/133,782 is a continuation of application No. 16/483,109, granted, now 10,906,985, previously published as PCT/US2018/016857, filed on Feb. 5, 2018.
Claims priority of provisional application 62/454,992, filed on Feb. 6, 2017.
Prior Publication US 2021/0230291 A1, Jul. 29, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/555 (2006.01); A61K 47/60 (2017.01); C07K 14/56 (2006.01); C07K 16/28 (2006.01)

CPC C07K 14/555 (2013.01) [A61K 47/60 (2017.08); C07K 14/56 (2013.01); C07K 16/2887 (2013.01); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/569 (2013.01); C07K 2317/92 (2013.01); C07K 2319/02 (2013.01); C07K 2319/30 (2013.01)]

6 Claims

1. A chimeric protein comprising:

(a) a variant consensus interferon comprising the amino acid sequence of SEQ ID NO: 2 and having a R150A mutation; and

(b) one or more targeting moieties, said targeting moieties comprising recognition domains comprising single-domain antibodies which specifically bind to target antigens or receptors; and

wherein the variant consensus interferon and the one or more targeting moieties are optionally connected with one or more linkers.